title: The autosomal dominant hypophosphatemic rickets R176Q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency.
abstract: Missense mutations in fibroblast growth factor 23 (FGF23) are the cause of autosomal dominant hypophosphatemic rickets (ADHR). The mutations (R176Q, R179W, and R179Q) replace Arg residues within a subtilisin-like proprotein convertase (SPC) cleavage site (RXXR motif), leading to protease resistance of FGF23. The goals of this study were to examine in vivo the biological potency of the R176Q mutant FGF23 form and to characterize alterations in homeostatic mechanisms that give rise to the phenotypic presentation of this disorder. For this, wild type and R176Q mutant FGF23 were overexpressed in the intact animals using a tumor-bearing nude mouse system. At comparable circulating levels, the mutant form was more potent in inducing hypophosphatemia, in decreasing circulating concentrations of 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)), and in causing rickets and osteomalacia in these animals compared with wild type FGF23. Parameters of calcium homeostasis were also altered, leading to secondary hyperparathyroidism and parathyroid gland hyperplasia. However, the raised circulating levels of parathyroid hormone were ineffective in normalizing the reduced 1,25(OH)(2)D(3) levels by increasing renal expression of 25(OH)D(3)-1alpha-hydroxylase (Cyp40) to promote its synthesis and by decreasing that of 25(OH)D(3)-24-hydroxylase (Cyp24) to prevent its catabolism. The findings provide direct in vivo evidence that missense mutations from ADHR kindreds are gain-of-function mutations that retain and increase the protein's biological potency. Moreover, for the first time, they define a potential role for FGF23 in dissociating parathyroid hormone actions on mineral fluxes and on vitamin D metabolism at the level of the kidney.
authors.affiliation: Division of Endocrinology, Department of Medicine and Lady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, McGill University, Montréal, Québec H3T 1E2, Canada.
authors.forename: Xiu-Ying
authors.initials: XY
authors.lastname: Bai
authors.forename: Dengshun
authors.initials: D
authors.lastname: Miao
authors.forename: David
authors.initials: D
authors.lastname: Goltzman
authors.forename: Andrew C
authors.initials: AC
authors.lastname: Karaplis
mesh_terms: D000818:Animals; D001120:Arginine / Q000737:chemistry*; D015152:Blotting, Northern; D016466:CHO Cells; D002117:Calcitriol / Q000494:pharmacology; D002455:Cell Division; D003001:Cloning, Molecular; D006224:Cricetinae; D018076:DNA, Complementary / Q000378:metabolism; D000089703:Fibroblast Growth Factor-23; D005346:Fibroblast Growth Factors / Q000235:genetics*; D005822:Genetic Vectors; D006801:Humans; D006961:Hyperparathyroidism / Q000378:metabolism; D007091:Image Processing, Computer-Assisted; D007150:Immunohistochemistry; D007684:Kidney Tubules / Q000378:metabolism; D051379:Mice; D008819:Mice, Nude; D009154:Mutation; D020125:Mutation, Missense; D010018:Osteomalacia / Q000378:metabolism; D010641:Phenotype; D012260:Ribonucleases / Q000378:metabolism; D012279:Rickets / Q000235:genetics*; D013997:Time Factors
chemical_list: D018076:DNA, Complementary; C000717427:FGF23 protein, human; C000717428:Fgf23 protein, mouse; D005346:Fibroblast Growth Factors; D000089703:Fibroblast Growth Factor-23; D001120:Arginine; D012260:Ribonucleases; D002117:Calcitriol